Capital Advisors Inc. OK Purchases 4,552 Shares of Stryker Corporation (NYSE:SYK)

Capital Advisors Inc. OK grew its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 3.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,529 shares of the medical technology company's stock after acquiring an additional 4,552 shares during the period. Capital Advisors Inc. OK's holdings in Stryker were worth $56,034,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. Assetmark Inc. grew its holdings in Stryker by 28.1% during the 4th quarter. Assetmark Inc. now owns 1,298 shares of the medical technology company's stock valued at $467,000 after purchasing an additional 285 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after purchasing an additional 523 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its holdings in Stryker by 9.1% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 1,819 shares of the medical technology company's stock valued at $655,000 after purchasing an additional 152 shares in the last quarter. Finally, AMF Tjanstepension AB acquired a new stake in Stryker during the 4th quarter valued at $1,496,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Shares of Stryker stock traded down $2.86 on Tuesday, reaching $389.65. The stock had a trading volume of 1,195,342 shares, compared to its average volume of 1,350,522. The business's 50-day moving average price is $383.44 and its two-hundred day moving average price is $376.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market cap of $148.73 billion, a P/E ratio of 52.66, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the business posted $2.50 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SYK. Citigroup reissued a "buy" rating and set a $455.00 price objective (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm lifted their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $428.55.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.